BioMarin Pharmaceutical (BMRN) to Release Quarterly Earnings on Thursday

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) is projected to announce its earnings results before the market opens on Thursday, May 1st. Analysts expect the company to announce earnings of $0.95 per share and revenue of $741.84 million for the quarter. BioMarin Pharmaceutical has set its FY 2025 guidance at 4.200-4.400 EPS.Investors interested in listening to the company's conference call can do so using this link.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last posted its quarterly earnings results on Wednesday, February 19th. The biotechnology company reported $0.72 EPS for the quarter, topping analysts' consensus estimates of $0.54 by $0.18. BioMarin Pharmaceutical had a net margin of 14.96% and a return on equity of 9.91%. The firm had revenue of $747.31 million for the quarter, compared to analysts' expectations of $711.05 million. On average, analysts expect BioMarin Pharmaceutical to post $3 EPS for the current fiscal year and $4 EPS for the next fiscal year.

BioMarin Pharmaceutical Trading Up 0.6 %

BMRN traded up $0.35 on Friday, reaching $59.17. 1,247,162 shares of the company traded hands, compared to its average volume of 1,886,222. The company has a market cap of $11.29 billion, a P/E ratio of 26.90, a price-to-earnings-growth ratio of 0.61 and a beta of 0.30. The company has a quick ratio of 2.62, a current ratio of 5.33 and a debt-to-equity ratio of 0.11. BioMarin Pharmaceutical has a one year low of $52.93 and a one year high of $94.85. The firm has a fifty day simple moving average of $66.74 and a two-hundred day simple moving average of $66.24.

Analyst Ratings Changes

Several brokerages recently issued reports on BMRN. Royal Bank of Canada reissued a "sector perform" rating and issued a $70.00 price objective on shares of BioMarin Pharmaceutical in a research note on Thursday, February 20th. Citigroup increased their target price on BioMarin Pharmaceutical from $81.00 to $82.00 and gave the company a "neutral" rating in a research report on Thursday, February 20th. Cantor Fitzgerald reissued an "overweight" rating and issued a $90.00 price target on shares of BioMarin Pharmaceutical in a research report on Thursday, February 20th. Scotiabank raised their price objective on BioMarin Pharmaceutical from $78.00 to $80.00 and gave the company a "sector perform" rating in a research report on Thursday, February 20th. Finally, Bank of America boosted their target price on shares of BioMarin Pharmaceutical from $99.00 to $103.00 and gave the stock a "buy" rating in a report on Thursday, February 20th. Seven equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $94.00.

Insider Buying and Selling

In other BioMarin Pharmaceutical news, CAO Erin Burkhart sold 1,344 shares of BioMarin Pharmaceutical stock in a transaction on Monday, February 24th. The shares were sold at an average price of $68.38, for a total transaction of $91,902.72. Following the sale, the chief accounting officer now owns 13,105 shares of the company's stock, valued at $896,119.90. The trade was a 9.30 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.85% of the stock is currently owned by insiders.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.